# Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision.

**Autores:** Habibi Mehran, Haffty Bruce G, Formenti Silvia C
**Revista:** NPJ Breast Cancer (2025)
**PMID:** 41193475 | **PMCID:** PMC12589602
**DOI:** [10.1038/s41523-025-00819-7](https://doi.org/10.1038/s41523-025-00819-7)
**Fuente:** PubMed Central (open access)

## Relevancia
Estudio sobre manejo axilar post-NAC en cáncer de mama cN+. Implicaciones para radioterapia regional post-NAC según respuesta nodal.

## Abstract
The NSABP B-51/RTOG 1304 trial represents a paradigm shift in breast cancer management, showing that patients achieving nodal clearance after neoadjuvant chemotherapy derive no added benefit from regional nodal irradiation. These results challenge long-standing practice, promotes de-escalation, and raise biologically significant questions, particularly regarding immunologic mechanisms and clinical subgroup variations.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12589602/

---
*Datos de PubMed. Citar: doi 10.1038/s41523-025-00819-7*
